Malignant tumor, vomiting
Conditions
Interventions
Control group (including dexamethasone group):None
Other solution group:None
Exposure group (the group without dexamethasone):None
Sponsors
Anqing first People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients with malignant tumors confirmed by pathology; 2.Receiving anti-tumor treatment through immunotherapy combined with chemotherapy; 3.The treatment plan has been rated as a medium or high-risk plan for the occurrence of vomiting. 4.Age > 18 years old; 5.Expected survival of more than 3 months;
Exclusion criteria
Exclusion criteria: 1.Patients with a history of severe mental illness or those who cannot cooperate with the information registration for treatment; 2.Patients with vomiting caused by other internal medical conditions or non-tumor-related reasons (such as severe gastrointestinal obstruction, acute gastroenteritis, acute poisoning, etc.) are also included in this group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vomiting completely relieved; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Immune function: lymphocyte subsets (CD3, CD4, CD8, CD4/CD8 ratio) and cytokine levels (IL-2, IL-6, TNF-a);Changes in nausea control status and functional living scale scores of patients;Selection bias caused by physician individualization and patient preference on guideline-standard antiemetic prophylaxis, and its reasons;The incidence of adverse events in the "dexamethasone" treatment group and the "containing dexamethasone" treatment group; | — |
Countries
China
Contacts
Public ContactJiawen Yu
Anqing first People's Hospital
Outcome results
None listed